Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Intellia Therapeutics Q3 EPS $(0.92) Beats $(0.99) Estimate, Sales $13.782M Miss $15.185M Estimate

Author: Benzinga Newsdesk | November 06, 2025 05:05pm
Intellia Therapeutics (NASDAQ:NTLA) reported quarterly losses of $(0.92) per share which beat the analyst consensus estimate of $(0.99) by 7.35 percent. This is a 31.34 percent increase over losses of $(1.34) per share from the same period last year. The company reported quarterly sales of $13.782 million which missed the analyst consensus estimate of $15.185 million by 9.24 percent. This is a 51.27 percent increase over sales of $9.111 million the same period last year.

Posted In: NTLA


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist